Presbia to Participate in Jefferies 2017 Global Healthcare Conference
May 30 2017 - 9:30PM
Business Wire
Presbia PLC (NASDAQ:LENS), an ophthalmic device company and
leader in near-vision restoration that has developed and is
currently marketing the Presbia Flexivue Microlens™, a proprietary
optical lens implant for treating presbyopia, announced today that
Todd Cooper, President and CEO, is scheduled to present at the
Jefferies 2017 Global Healthcare Conference on Tuesday, June 6th,
at 11:30 a.m. ET. The Conference will take place in New York at the
Grand Hyatt from June 6 to 9, 2017. Mr. Cooper will be available
for one-on-one meetings at the Conference.
The presentation will provide an update on the status of the
U.S. clinical trial. “Presbia plans on submitting the fourth and
final module of the IDE study to the FDA in Q4, which is a major
milestone towards approval of the Presbia Flexivue Microlens™ in
the U.S.,” said Mr. Cooper.
Forward-Looking Statements
Information provided and statements contained in this press
release that are not purely historical are forward-looking
statements. Such forward-looking statements only speak as of the
date of this press release and Presbia assumes no obligation to
update the information included in this press release. Statements
made in this press release that are forward looking in nature may
involve risks and uncertainties. Accordingly, readers are cautioned
that any such forward-looking statements are not guarantees and are
subject to certain risks, uncertainties and assumptions that are
difficult to predict. Although Presbia believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Unless otherwise required by law,
Presbia also disclaims any obligation to update its view of any
such risks or uncertainties or to announce publicly the result of
any revisions to the forward-looking statements made in this press
release.
About Presbia
Presbia PLC (NASDAQ:LENS) is an ophthalmic device company that
has developed and is currently marketing the presbyopia-correcting
Presbia Flexivue Microlens™, a miniature lens that is implanted in
a corneal pocket created by a femtosecond laser. The Presbia
Flexivue Microlens™ has received a CE mark for the European
Economic Area, allowing the lens to be marketed in over 30
countries across Europe. A staged pivotal U.S. clinical trial for
the Presbia Flexivue Microlens™ commenced in 2014.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170530006468/en/
Presbia PLCMonica Yamada,
323-860-4903monica@presbia.com
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2024 to Jul 2024
Presbia (CE) (USOTC:LENSF)
Historical Stock Chart
From Jul 2023 to Jul 2024